Ralph E Parchment
Overview
Explore the profile of Ralph E Parchment including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gross A, OSullivan Coyne G, Dombi E, Tibery C, Herrick W, Martin S, et al.
Nat Med
. 2025 Jan;
31(1):105-115.
PMID: 39762421
The MEK inhibitor selumetinib induces objective responses and provides clinical benefit in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). To evaluate whether similar outcomes were possible...
2.
ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models
Schmid S, Russell Z, Yamashita A, West M, Parrish A, Walker J, et al.
Cell Rep
. 2024 Oct;
43(10):114829.
PMID: 39365700
Pediatric-type high-grade gliomas frequently harbor gene fusions involving receptor tyrosine kinase genes, including neurotrophic tyrosine kinase receptor (NTRK) fusions. Clinically, these tumors show high initial response rates to tyrosine kinase...
3.
ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models
Schmid S, Russell Z, Yamashita A, West M, Parrish A, Walker J, et al.
bioRxiv
. 2024 Apr;
PMID: 38558981
Pediatric-type high-grade gliomas frequently harbor gene fusions involving receptor tyrosine kinase genes, including neurotrophic tyrosine kinase receptor (NTRK) fusions. Clinically, these tumors show high initial response rates to tyrosine kinase...
4.
Krushkal J, Zhao Y, Roney K, Zhu W, Brooks A, Wilsker D, et al.
Epigenetics
. 2024 Feb;
19(1):2309824.
PMID: 38369747
Histone deacetylases (HDACs) and sirtuins (SIRTs) are important epigenetic regulators of cancer pathways. There is a limited understanding of how transcriptional regulation of their genes is affected by chemotherapeutic agents,...
5.
Mittra A, Coyne G, Zlott J, Kummar S, Meehan R, Rubinstein L, et al.
Cancer Chemother Pharmacol
. 2023 Nov;
93(3):177-189.
PMID: 38010394
Purpose: Talazoparib is an inhibitor of the poly (ADP-ribose) polymerase (PARP) family of enzymes and is FDA-approved for patients with (suspected) deleterious germline BRCA1/2-mutated, HER2‑negative, locally advanced or metastatic breast...
6.
Chen A, Sharon E, OSullivan-Coyne G, Moore N, Foster J, Hu J, et al.
N Engl J Med
. 2023 Sep;
389(10):911-921.
PMID: 37672694
Background: Alveolar soft part sarcoma (ASPS) is a rare soft-tissue sarcoma with a poor prognosis and no established therapy. Recently, encouraging responses to immune checkpoint inhibitors have been reported. Methods:...
7.
Tyurina Y, Kapralov A, Tyurin V, Shurin G, Amoscato A, Rajasundaram D, et al.
Redox Biol
. 2023 Mar;
61:102650.
PMID: 36870109
Growing cancer cells effectively evade most programs of regulated cell death, particularly apoptosis. This necessitates a search for alternative therapeutic modalities to cause cancer cell's demise, among them - ferroptosis....
8.
Manzo J, Puhalla S, Pahuja S, Ding F, Lin Y, Appleman L, et al.
Cancer Chemother Pharmacol
. 2022 Apr;
89(5):721-735.
PMID: 35435472
Purpose: BRCA1 or BRCA2 mutated cancers (BRCAmut) have intrinsic sensitivity to PARP inhibitors due to deficiency in homologous recombination-mediated DNA repair. There are similarities between BRCAmut and BRCAwt ovarian and...
9.
Chen Z, Zheng L, Chen Y, Liu X, Kawakami M, Mustachio L, et al.
Cancer Biol Ther
. 2022 Apr;
23(1):265-280.
PMID: 35387560
Cancer metastasis is a major cause of cancer-related mortality. Strategies to reduce metastases are needed especially in lung cancer, the most common cause of cancer mortality. We previously reported increased...
10.
PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
OSullivan Coyne G, Karlovich C, Wilsker D, Voth A, Parchment R, Chen A, et al.
Onco Targets Ther
. 2022 Mar;
15:165-180.
PMID: 35237050
Poly(ADP-ribose) polymerase inhibitors (PARPi) have been in clinical use since 2014 for certain patients with germline mutations, but as evidence and approvals for their use in a wider range of...